Product Description: Ibalizumab (TMB-355) is a humanised IgG4 monoclonal antibody that prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research[1].
Applications: COVID-19-anti-virus
Formula: N/A
References: [1]Anthony Markham. Ibalizumab: First Global Approval. Drugs. 2018 May;78(7):781-785.